Answers are grounded in this paper and cite their sources.
There is debate about what is the optimal treatment for operable stage I non-small cell lung cancer (NSCLC). Although surgery has been the standard of care for centuries, recent retrospective and prospective randomized studies indicated that stereotactic ablative radiotherapy (SABR) could be an option for this group of patients with similar survival and less toxicities. However, to change the standard of care, more studies are needed and participating ongoing larger randomized studies is the best approach to resolve this controversy.
No takes yet. Share an insight, caveat, or question.
Moghanaki et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: